Jessica Sharpe (@jesmezz) 's Twitter Profile
Jessica Sharpe

@jesmezz

Heme/Onc fellow at VUMC. Former chief internal medicine resident at Ohio State. Aspiring breast oncologist. Views my own.

ID: 1242076469658112001

calendar_today23-03-2020 13:12:05

60 Tweet

159 Followers

135 Following

OncoAlert (@oncoalert) 's Twitter Profile Photo

The #OncoAlertTopTweet ๐ŸšจDay 3โƒฃ #SABCS23 Tweet by Our OncoAlert faculty Stephanie Graff, MD, FACP, FASCO ๐Ÿ‡บ๐Ÿ‡ธ Presentation by our own Matteo Lambertini, MD PhD ๐Ÿ‡ฎ๐Ÿ‡น No detrimental prognostic effect of pregnancy after BC in BRCA carriers๐Ÿงฌ Link jamanetwork.com/journals/jama/โ€ฆ

Stephanie Graff, MD, FACP, FASCO (@drsgraff) 's Twitter Profile Photo

Abemaciclib MonarchE benefited patients across intrinsic molecular subtypes, in both high- and low-risk scores using inferred Oncotype MYC amplified tumors may represent a group who derive less benefit, but further analysis needed. #SABCS23 OncoAlert

Abemaciclib MonarchE benefited patients across intrinsic molecular subtypes, in both high- and low-risk scores using inferred Oncotype 
MYC amplified tumors may represent a group who derive less benefit, but further analysis needed.
#SABCS23 <a href="/OncoAlert/">OncoAlert</a>
Neil Vasan (@neilvasan) 's Twitter Profile Photo

Few thoughts on INAVO120 data presented today SABCS. #bscm OncoAlert PIK3CA Path Breakers 1. This is a potent triplet combination with a doubling of PFS (delta PFS 8 mo). OS trending in positive direction.

Jessica Sharpe (@jesmezz) 's Twitter Profile Photo

Fantastic final discussion at #SABCS23 about what to do in the trenches Monday morning based on what we learned this week. Loved hearing from some amazing med onc, rad onc, and surg onc physicians as well as Leslie, a patient advocate living with MBC for 11 years.

Jessica Sharpe (@jesmezz) 's Twitter Profile Photo

Great final morning at #SABCS23โ€™s career development day. Loved these โ€œlife lessonsโ€ from Dr. Mittendorf

Great final morning at #SABCS23โ€™s career development day. Loved these โ€œlife lessonsโ€ from Dr. Mittendorf
๐‚๐ก๐š๐ง๐๐ฅ๐ž๐ซ ๐๐š๐ซ๐ค ๐Œ๐ƒ ๐…๐€๐‚๐ (@cparkmd) 's Twitter Profile Photo

โญ๏ธTHRILLED to host this meeting w/ my good friend Dr. Cathy Eng in beautiful Nashville. Join us as we have the LEADING thought leaders discuss the latest data including a special appearance by the Oncology Brothers Register here๐Ÿ‘‡ web.cvent.com/event/c61fd6ddโ€ฆ Dr. Cathy Eng David R. Spigel, MD, FASCO

โญ๏ธTHRILLED to host this meeting w/ my good friend Dr. Cathy Eng in beautiful Nashville.  Join us as we have the LEADING thought leaders discuss the latest data including a special appearance by the <a href="/OncBrothers/">Oncology Brothers</a> 
Register here๐Ÿ‘‡
web.cvent.com/event/c61fd6ddโ€ฆ

<a href="/CathyEngMD/">Dr. Cathy Eng</a> <a href="/DavidRSpigel/">David R. Spigel, MD, FASCO</a>
๐‚๐ก๐š๐ง๐๐ฅ๐ž๐ซ ๐๐š๐ซ๐ค ๐Œ๐ƒ ๐…๐€๐‚๐ (@cparkmd) 's Twitter Profile Photo

โญ๏ธMy friend Dr. Cathy Eng and I would like to THANK our friends, colleagues, attendees, MEC team, and industry sponsors for making our MLS Nashville 2025 ASCO review a FUN educational event. #Reels David R. Spigel, MD David R. Spigel, MD, FASCO Christine M. Lovly, MD, PhD, FASCO

Mirrors of Medicine (@mirrorsmed) 's Twitter Profile Photo

Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers link.springer.com/article/10.100โ€ฆ In this large real-world study of 415 patients with early-stage or locally advanced triple-negative

Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers

link.springer.com/article/10.100โ€ฆ

In this large real-world study of 415 patients with early-stage or locally advanced triple-negative